Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Inovio Pharmaceuticals is collaborating with Beijing Advaccine Biotechnology to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected thousands more in China to date.

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio recently announced that it is developing INO-4800 through Phase I human testing in the US to evaluate safety and immunogenicity with the support of an initial grant up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Inovio plans to rapidly develop INO-4800 against the new coronavirus and has already started preclinical testing and preparations for clinical product manufacturing. The goal of this collaboration is to leverage Advaccine's expertise to run a Phase I trial in China in parallel with Inovio's clinical development efforts in the US. Inovio and Advaccine will also work together to attract additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of future testing of INO-4800.

Dr J. Joseph Kim, Inovio's President & CEO, said: "Our collaboration with Beijing Advaccine and its Founder, Emeritus Professor Bin Wang from the prestigious Fudan University and China's premier DNA vaccine expert, will tremendously accelerate our coronavirus vaccine INO-4800 development in China because of its expertise and experience with regulatory authorities and clinical trial management. This collaboration allows us to enter China and deliver our vaccine into the areas where they need it most as soon as possible. Our shared goal is to utilize both companies' expertise in developing vaccines for emerging infectious diseases and hopefully achieve an accelerated regulatory approval for INO-4800."

Inovio's participation in this developing effort is based on the ideal suitability of its DNA medicine platform to rapidly develop vaccines against emerging viruses with pandemic potential, proven vaccine development capabilities, and a strong track record of rapidly generating promising countermeasures against previous pandemic threats. Inovio was the first to advance its vaccine (INO-4700) against MERS-CoV, a related coronavirus, into evaluation in humans. Inovio is currently preparing to initiate a Phase II trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred. Those efforts are supported by CEPI funding and partnership.

In a recently published paper in Lancet Infectious Diseases, Inovio's Phase I study of INO-4700, its MERS-CoV vaccine, demonstrated it was well-tolerated and furthermore induced high levels of antibody responses in approximately 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.

Read More

Related news

2020 - a year for 'big answers' rather than 'big data'

2020 - a year for 'big answers' rather than 'big data'

7 Feb 2020

Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

Read more 
AstraZeneca embarks on $1bn zero carbon strategy

AstraZeneca embarks on $1bn zero carbon strategy

24 Jan 2020

The programme will include the launch of next-generation respiratory inhalers, which will use near-zero Global Warming Potential propellants.

Read more 
Diabetes diagnosis - now a matter of sweat and tears?

Diabetes diagnosis - now a matter of sweat and tears?

21 Jan 2020

No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

Read more 
2019, the year that got serialization done!

2019, the year that got serialization done!

17 Dec 2019

The past 12 months have been busy as many companies fought to comply with serialization regulations.

Read more 
Edible barcodes - it's Tru!

Edible barcodes - it's Tru!

10 Dec 2019

Smart tags on pills set to improve supply chain security and patient adherence.

Read more 
US Pharmaceutical industry continues to shine according to CPhI 2019 Annual Report

US Pharmaceutical industry continues to shine according to CPhI 2019 Annual Report

9 Dec 2019

The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceuti...

Read more 
UK experiences a 'baby boom' of new life sciences ventures

UK experiences a 'baby boom' of new life sciences ventures

2 Dec 2019

Unprecedented levels of investment cited as a major force driving the expansion.

Read more 
UK’s life sciences sector continues to attract talent despite Brexit fear

UK’s life sciences sector continues to attract talent despite Brexit fear

26 Nov 2019

The largest area of growth has been within biotechnology companies, where job openings increased by 35%.

Read more 
Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
‘FDA should withdraw ANDAs’ says expert

‘FDA should withdraw ANDAs’ says expert

21 Oct 2019

CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Read more